Supreme Court justices expressed skepticism that patent settlements between brand-name and generic-drug makers should be unilaterally declared anti-competitive, writes Bruce Japsen. Generic drugs have cut into profits as Big Pharma has struggled to fill pipelines, and the news boosted stock values. Big Pharma is increasingly focused on developing complex biologic drugs to treat diseases such as cancer, multiple sclerosis and autoimmune disorders.
Biologics, SCOTUS' take on patent settlements boost Big Pharma
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||